Skip to main content
Utility Menu
Investors
Newsroom
Contact Us
Regional Navigation
Global Sites
Switzerland
Deutsch
English
Français
Italiano
UK
English
United States
English
Toggle Menu Button
Utility Menu
Investors
Newsroom
Contact Us
Regional Navigation
Global Sites
Switzerland
Deutsch
English
Français
Italiano
UK
English
United States
English
Social Links
Twitter
LinkedIn
Instagram
Facebook
Main navigation
Our Disease Areas
Duchenne Muscular Dystrophy
Limb-girdle Muscular Dystrophy
Charcot-Marie-Tooth Disease
Our Science
Gene Therapy Engine
RNA Platform
Gene Editing
Manufacturing
Strategic Partnerships
Our Products & Pipeline
Products
Pipeline
Clinical Trials
Treatment Access
About Us
Leadership
Patient Affairs
Corporate Responsibility
Grants & Giving
Global Locations
Contact Us
Join Us
Career Opportunities
Toggle Menu Button
Search
Awards & Recognitions: Sarepta recognized for innovation and industry leadership
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
LGMD Grant Award Program
Route 79 Scholarship Program
When time is muscle: One dad shares his story to advocate for Duchenne newborn screening
Sarepta Therapeutics anuncia la convocatoria de solicitudes para el Programa de concesión de subvenciones para LGMD 2024
Sarepta Therapeutics Announces Call for Applications for the 2024 LGMD Grant Award Program
Pagination
First page
« First
Previous page
‹ Previous
…
Page
3
Page
4
Page
5
Page
6
Current page
7
Page
8
Page
9
Page
10
Page
11
…
Next page
Next ›
Last page
Last »